Immunophotonics wins China patent for IP-001 combination therapy

Immunophotonics said China’s patent office granted protection for its lead asset IP-001 in combination with checkpoint inhibitors for solid tumors. The new patent expands the company’s global intellectual property footprint as it advances clinical development and looks toward broader market and partnership opportunities. Why it matters: - The China patent extends protection for Immunophotonics’ core platform technology into one of the world’s largest healthcare markets. - The filing strengthens the company’s position around IP-001, its lead investigational asset, as the program moves through clinical development. - The patent also supports the company’s broader strategy for combination therapies and future commercialization. What happened: - The China National Intellectual Property Administration issued a patent titled “Semi-Synthetic Biopolymers for Use in Stimulating the Immune System.” - The patent covers use of IP-001 with checkpoint inhibitors for the treatment of solid tumors. - Immunophotonics announced the grant on June 16, 2026. - The company is a clinical-stage biotech focused on immunostimulatory therapies designed to enhance routine tumor destruction treatments. The details: - The Chinese patent adds to previously secured intellectual property rights in Europe. - Immunophotonics said the new filing expands global protection for its proprietary platform technology. - The company said a layered patent estate is central to its long-term development approach. - IP-001 is designed to retain tumor antigens at the site of injection, boost antigen presentation and immune cell activation, and drive a systemic anti-tumor immune response. - Immunophotonics’ data suggest IP-001 may enhance anti-tumor activity when combined with immune checkpoint inhibitors versus checkpoint inhibitor therapy alone. - The company said its patent strategy is intended to protect both the therapeutic potential and commercial viability of IP-001. - Immunophotonics is privately owned and based in St. Louis, Missouri, with European headquarters in Bern, Switzerland. - The company said IP-001 is currently assessed in multiple clinical trials. - The company’s website is more information . Between the lines: - The patent award gives Immunophotonics stronger legal footing in China as it positions IP-001 for global development. - The move also signals that the company is building around combination-therapy use cases, not just a single-product strategy. - Alexander Hurst, chief corporate officer and general counsel, said the China expansion reflects the strength of the science and the company’s commitment to a robust patent portfolio. - Robert Arch, president, said the broader patent footprint could support regional reach and clinical partnerships to enable treatment of Chinese patients after tumor ablation. What’s next: - Immunophotonics plans to keep advancing its clinical programs while strengthening the intellectual property foundation behind them. - The company’s next development steps likely hinge on clinical data, regulatory progress, and future partnership activity in key markets. - Immunophotonics said it will continue pursuing patent coverage across global jurisdictions to support future development pathways and combination-therapy strategies. The bottom line: - The China patent marks a meaningful IP win for Immunophotonics and broadens protection for a lead cancer program with global ambitions.